Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

Fig. 3

Acyl-GIP regulates adipocyte size and gene expression in subcutaneous fat of LDLR-/- mice. (A) Relative gWAT and iWAT GIPR gene expression of vehicle (gWAT n = 5; iWAT n = 4) and acyl-GIP treated LDLR-/- mice (gWAT n = 5; iWAT n = 4). (B) Volcano plot showing differential expression and its significance (-log10(p-Value), limma-trend) and (C) frequency distribution of adipocyte cell sizes (µm2) of gWAT from acyl-GIP (RNA sequencing n = 5; histology n = 7) versus vehicle (RNA sequencing n = 5; histology n = 6) treated LDLR-/- mice. (D) Volcano plot showing differential expression and its significance (-log10(p-Value), limma-trend) and (E) frequency distribution of adipocyte cell sizes (µm2) of iWAT from acyl-GIP (RNA sequencing n = 5; histology n = 4) versus vehicle treated LDLR-/- mice (RNA sequencing n = 5; histology n = 4). (F) Gene ontologies (p < 0.0001) and KEGG pathways (Pvalue < 0.001) that are down regulated by acyl-GIP in sc fat. Representative terms from Supplementary Table 2 are depicted

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840